Results 71 to 80 of about 148,764 (203)

Hypoxia Drives Dihydropyrimidine Dehydrogenase Expression in Macrophages and Confers Chemoresistance in Colorectal Cancer

, 2021
Colorectal adenocarcinoma is a leading cause of death worldwide, and immune infiltration in colorectal tumors has been recognized recently as an important pathophysiologic event.
Laverriere, Marie-Hélène, Marsili, Sabrina, Thomas, Fabienne, Gharzeddine, Khaldoun, Malier, Marie, Decaens, Thomas, Roth, Gael, Millet, Arnaud, Court, Magali   +8 more
core   +1 more source

Evolution of Dihydropyrimidine Dehydrogenase Diagnostic Testing in a Single Center during an 8-Year Period of Time

Current Therapeutic Research, 2019
: Objective: Fluoropyrimidine treatment can be optimized based on dihydropyrimidine dehydrogenase (DPD) activity. DPD dysfunction leads to increased exposure to active metabolites, which can result in severe or even fatal toxicity.
Marieke J.H. Coenen, PhD, Aimée D.C. Paulussen, PhD, Marc Breuer, BSc, Martijn Lindhout, BSc, Demis C.J. Tserpelis, BSc, Anja Steyls, BSc, Jörgen Bierau, PhD, Bianca J.C. van den Bosch, PhD   +7 more
doaj   +1 more source

Optimizing Outcomes in Elderly HNSCC: Efficacy of UFT Metronomic Therapy

Cancer Medicine, Volume 15, Issue 6, June 2026.
ABSTRACT Introduction Head and neck squamous cell carcinoma (HNSCC) remains a significant clinical challenge, especially in elderly patients with advanced‐stage disease and multiple comorbidities. Metronomic chemotherapy with oral tegafur‐uracil (UFT) offers a low‐toxicity maintenance option that may improve outcomes.
Hsu‐Lin Lee, Po‐Huang Chen, Yu‐Guang Chen, Jia‐Hong Chen, Tzu‐Chuan Huang, Ching‐Liang Ho, Ren‐Hua Ye   +6 more
wiley   +1 more source

Pyruvate dehydrogenase : its structure, function and interactions within the pyruvate dehydrogenase multienzyme complex [PDF]

, 2002
Pyruvate dehydrogenase multi-enzyme complex (PDHC) is member of a family of multienzyme complexes that catalyse the irreversible decarboxylation of various 2-oxoacid substrates to their corresponding acyl-CoA derivatives, NADH and C02.
Hengeveld, A.F.
core  

Identifying a Novel DPYD Polymorphism Associated with Severe Toxicity to 5-FU Chemotherapy in a Saudi Patient

Case Reports in Genetics, 2019
Dihydropyrimidine dehydrogenase (DPD) is the major enzyme in the catabolism of 5-Fluorouracil (5-FU) and its prodrug capecitabine. We report a 65-year-old female with rectal adenocarcinoma who experienced severe toxicities secondary to standard dose 5-FU
Nedal Bukhari, Faisal Azam, Mohammed Alfawaz, Mohammed Zahrani   +3 more
doaj   +1 more source

High-resolution melting analysis of the common c.1905+1G>A mutation causing dihydropyrimidine dehydrogenase deficiency and lethal 5-fluorouracil toxicity

Frontiers in Genetics, 2013
Dihydropyrimidine dehydrogenase (DPD) deficiency is a pharmacogenetic syndrome associated with life-threatening toxicity following exposure to the fluoropyrimidine drugs 5-fluorouracil (5-FU) and capecitabine (CAP), widely used for the treatment of ...
Emma eBorràs, Emma eDotor, Àngels eArcusa, Maria José eGamundi, Imma eHernan, Miguel ede Sousa Dias, Begoña eMañé, José A G Agúndez, Miguel eBlanca, Miguel eCarballo   +9 more
doaj   +1 more source

Carrier screening in the reproductive setting—Are there medical implications for the heterozygote?—A guide for clinicians

Pregnancy, Volume 2, Issue 3, May 2026.
Abstract Carrier screening for genetic conditions performed preconception or during pregnancy allows identification of fetal risk for inherited autosomal recessive and X‐linked conditions. The goal is to identify at‐risk patients/couples and offer them reproductive options such as preimplantation genetic diagnosis, prenatal testing, or targeted newborn
Emily B. Rosenfeld, Nicole Kasatkin, Bi Liu Yu, Milen Velinov, Justin S. Brandt, Elena Ashkinadze   +5 more
wiley   +1 more source

Limited Visibility and Perception of the Clinical Relevance of Clopidogrel Pharmacogenetics in Cardiology Literature

Clinical and Translational Science, Volume 19, Issue 5, May 2026.
ABSTRACT Clopidogrel is an antiplatelet agent widely utilized in cardiology. It is a prodrug activated in the liver by the cytochrome P450 isoform CYP2C19. Variability in the CYPC2C19 gene influences the activation and efficacy of clopidogrel. This is covered in guidelines from the Clinical Pharmacogenetics Implementation Consortium, the Dutch ...
Cinzia Dello Russo, Luigi Venetucci, Abisope Akintola, Dimitri Gagliardi, Ronnie Ramlogan, Munir Pirmohamed   +5 more
wiley   +1 more source

Polyphenol‐Based Biomaterials Against Cancer Radio/Chemotherapy‐Induced Intestinal Toxicity

Advanced NanoBiomed Research, Volume 6, Issue 4, April 2026.
Radiotherapy/chemotherapy often causes intestinal toxicity, impairing cancer patients’ quality of life and treatment efficacy. Polyphenols protect against this injury via multiple mechanisms, but face oral use limitations. This review outlines their protective mechanisms and delivery challenges, highlighting recent oral delivery advances and future ...
Jixu Lu, Jing Chen, Ji Zhu, Lixin Ru, Dongxiao Zhang   +4 more
wiley   +1 more source

Carcinogenic Medications: A Review of Specific Agents and Molecular Mechanisms of Carcinogenesis

Cancer Reports, Volume 9, Issue 4, April 2026.
ABSTRACT Background Pharmacovigilance has revealed an alarming correlation between certain medications and a higher risk of cancer. In this narrative review, included research from 2020 to 2025, along with a few seminal older studies, so that it provides a clear picture of which drugs actually set off cancer and mechanisms involved at the molecular ...
Desta Seyoum Tadesse, Kalkidan Tekletsadik, Berhan Begashaw, Awgichew Shewasinad Yehualashet, Awol Mekonnen Ali, Kassahun Dires Ayenew   +5 more
wiley   +1 more source